Rare disease clinical trials require a fundamentally different approach to site selection and feasibility. Small, geographically dispersed patient populations, delayed diagnoses, complex care pathways, and limited treatment centers make traditional landscape analysis insufficient.
For sponsors developing therapies in rare indications, identifying the right countries, sites, and investigators is critical to enrollment success — and to protecting timelines.
At Ergomed Clinical Research, we apply a patient-centered, three-pillar feasibility strategy designed specifically for rare disease trials.
Why Traditional Rare Disease Feasibility Is Not Enough
Conventional landscape analysis typically relies on:
- Published literature
- Clinical trial registries
- Epidemiology and prevalence data
- Historical site performance
- Key opinion leader (KOL) identification
While these data sources are essential, they rarely capture how care truly happens in the real world. They often miss:
- Actual patient referral pathways
- Centers that treat patients but do not publish extensively
- Local reimbursement or access barriers
- Cultural factors influencing trial participation
- Protocol-specific recruitment challenges
- Patient burden considerations impacting retention
In rare disease development, these gaps can result in inaccurate enrollment forecasts and costly delays.
A Three-Pillar Approach to Rare Disease Site Selection
To strengthen feasibility assessments and improve enrollment predictability, Ergomed integrates three complementary pillars into pre-award landscape analysis.
- 1) Data Intelligence
This foundational pillar leverages public, private, and proprietary data sources to assess:
- Competitive trial landscape
- Recruitment rates and timelines
- Historical site performance
- Centers of Excellence
- Epidemiology and geographic distribution
The result is a focused, data-driven shortlist of realistic, high-potential countries and sites.
- 2) Medic-to-Medic Outreach
Peer-to-peer physician dialogue adds critical human intelligence to feasibility.
Through medical-to-medical discussions, our clinical experts:
- Validate actual patient availability
- Assess site capacity and willingness
- Identify protocol design challenges early
- Evaluate inclusion/exclusion feasibility
- Understand competing trial pressures
This approach moves beyond theoretical projections to realistic enrollment modeling grounded in treating physician insight.
- 3) Patient Advocacy Organization Engagement
Rare disease trials cannot succeed without understanding the patient journey.
Early engagement with patient advocacy organizations (PAOs) provides:
- Real-world insight into care pathways
- Identification of trusted treating centers
- Understanding of meaningful endpoints
- Guidance on travel and logistical burden
- Cultural and regional participation dynamics
Local and country-specific patient organizations offer particularly granular intelligence — including healthcare navigation nuances, reimbursement realities, and trusted referral networks.
This patient-centered intelligence ensures site selection aligns with where patients are actually treated — not just where research is traditionally published.
The Impact on Rare Disease Enrollment and Retention
When site selection integrates data, physician insight, and patient advocacy engagement, sponsors benefit from:
- More accurate enrollment projections
- Faster site activation
- Reduced protocol-related recruitment barriers
- Improved patient retention
- Stronger long-term community trust
By synthesizing intelligence across all three pillars before award, Ergomed establishes realistic expectations and strengthens operational predictability from the outset.
The Future of Rare Disease Feasibility: Human Expertise Enhanced by AI
Emerging AI technologies — including real-world data platforms and digital site simulations — are beginning to enhance landscape analysis.
At Ergomed, AI-generated outputs are treated as analytical hypotheses that require expert validation. Human oversight, medical judgment, and patient engagement remain central to rare disease feasibility strategy.
Technology enhances expertise — it does not replace it.